A multisociety Delphi consensus statement on new fatty liver disease nomenclature
University of Chicago · The Graduate Center, CUNY · +78 more institutions
Abstract
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panellists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey…
Citation impact
- FWCI
- 535.12
- Percentile
- 100%
- References
- 34
Authors
53- MEMary E. RinellaCorresponding
University of Chicago
- JVJeffrey V. Lazarus
The Graduate Center, CUNY, Universitat de Barcelona, Barcelona Institute for Global Health, City University of New York
- VRVlad Ratziu
Fondation pour l’innovation en Cadiométabolisme et Nutrition, Sorbonne Université
- SFSven Francque
Antwerp University Hospital, University of Antwerp
- AJArun J. Sanyal
Virginia Commonwealth University
Topics & keywords
- Nomenclature
- Statement (logic)
- Fatty liver
- Delphi
- Consensus conference
- Medicine
- Disease
- Internal medicine
- Reduced inequalities
Funding
- UDU.S. Department of Veterans Affairs
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- AAAmerican Association for the Study of Liver Diseases
- GSGilead Sciences
- APAlnylam Pharmaceuticals
- CUCity University of New York
- EUEmory University
- CCCincinnati Children's Hospital Medical Center
- WSWashington State University
- UOUniversity of Florida
- UOUniversity of Cincinnati
- LHLondon Health Sciences Centre
- UDUniversidad de Sevilla
- VCVirginia Commonwealth University
- RPRegeneron Pharmaceuticals
- UHUniversity Hospital Southampton NHS Foundation Trust
- UDUniversità degli Studi di Milano
- IHInova Health System
- CHChildren's Healthcare of Atlanta
- QBQIMR Berghofer Medical Research Institute
- UHUniversity Hospitals Birmingham NHS Foundation Trust
- NNovavax
- BPBoston Pharmaceuticals
- VLVerily Life Sciences
- NBNGM Biopharmaceuticals
- AUAmsterdam University Medical Centers
- NINational Institute for Health and Care Research
- UOUniversity of Southampton
- UOUniversity of Oxford
- NUNewcastle University
- UOUniversity of Birmingham
- UOUniversity of Queensland
- UVUniversiteit van Amsterdam
- YUYonsei University
- CNConsejo Nacional de Investigaciones Científicas y TécnicasAward: 2021-2023
- HDHeinrich-Heine-Universität Düsseldorf
- NUNewcastle upon Tyne Hospitals NHS Foundation Trust
- HUHelwan University
- NNNovo Nordisk
- CUChinese University of Hong Kong
- NANational and Kapodistrian University of Athens
- UDUniversidade de Lisboa
- UDUniversitat de Barcelona
- UOUniversity of Cape Town
- UAUniversiteit Antwerpen
- EAEuropean Association for the Study of the Liver
- FIFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- UAUniversidad Abierta Interamericana
- SPSun Pharma
- SUSorbonne Université
- GGenentech
- PSPritzker School of Medicine
- UOUniversity of California, Irvine
- SOSchool of Medicine, Indiana University
- COCollege of Medicine, University of Cincinnati
- CFCenter for Innovations in Quality, Effectiveness and Safety
- LLeibniz-Gemeinschaft
- YUYonsei University College of Medicine
- IDInstitut de Cardiométabolisme et Nutrition
- FOFaculty of Medicine and Health, University of Sydney